Melissa Fazzari, PhD
Director of Biostatistics
Academic Faculty Appointments
Assistant Clinical Professor (voluntary appointment) of Preventive Medicine, Stony Brook University
Assistant Clinical Professor (voluntary appointment) of Epidemiology and Population Health, Albert Einstein College of Medicine
222 Station Plaza North, Suite 300, Mineola, NY 11501
Dr. Melissa Fazzari obtained her Ph.D. in Applied Mathematics and Statistics from Stony Brook University, and a B.A. in Mathematics from Boston University. Previously, she was an Assistant Professor in the Department of Preventive Medicine at Stony Brook University and in the Departments of Epidemiology and Genetics at Albert Einstein College of Medicine. She has been teaching basic to advanced Biostatistics for over 10 years, serving as co-director for the CRTP Biostatistics course at Einstein and teaching in the clinical trials course at Stony Brook. Dr. Fazzari has been a biostatistics consultant for many major medical institutions, including NYU, Mount Sinai, and Winthrop. She joined Winthrop in 2013 as the director of the Biostatistics Department, and focuses on overseeing the activities of the group as well as collaborating with Winthrop investigators. Dr. Fazzari also currently works with researchers at Mount Sinai developing prognostic models using methylation and gene expression data to predict treatment response and other patient outcomes in Mantle Cell Lymphoma.
Description of Research Interests/Activities
Dr. Fazzari's background includes 15 years' experience as a biostatistician for major research projects involving cancer, epigenomics, and the epidemiology of HPV progression in a large study of HIV-positive women. Dr. Fazzari's research interests are focused in clinical trial methodology as well as the analysis of high dimensional molecular data. Recently, she developed sample size formulae for three-level hierarchical clinical trials and has explored the robustness of these formulae to common real-world issues in clinical trials including missing data and treatment group imbalances. In the analysis of high-dimensional molecular data, Dr. Fazzari has expertise in the analysis, aggregation, and integration of data from genome- and epigenome-wide studies, developing a prioritization approach in methylation-based studies to incorporate biological priors with statistical testing in order to better identify novel candidate loci.
Areas of Experience
Research Team Members
The Biostatistics team consists of three Biostatisticians. Melissa Fazzari, Ph.D., Shah Islam, M.S. and Rose Calixte, Ph.D.
1. Fazzari M, Heller G, Scher HI. The phase II/III transition. Toward the proof of efficacy in cancer clinical trials. Controlled Clinical Trials, Aug 2000, 21(4) p360-8 [PMID: 10913810]
2. Mazumdar M, Fazzari M, Panageas KS. A standardization method to adjust for the effect of patient selection in phase II clinical trials. Statistics in Medicine, Mar 30 2001, 20(6) p883-92 [PMID: 11252010]
3. Fazzari MJ, Greally JM. Epigenomics: Beyond CpG Islands. Nature Reviews Genetics 5, 446 - 455 (2004) [PMID: 15153997]
4. Shuter J, Fazzari M. Patient Predictions Correlate with Actual CD4+ Lymphocyte and HIV-1 Viral Load Changes in an Urban, HIV-infected Clinic Population. AIDS Patient Care STDS (2004); 18(9):520-
5. Sparano J, Fazzari M, Childs J. Clinical application of molecular profiling in breast cancer. Future Oncology (2005); 1(4):485-496.[PMID: 16556025]
6. Ahn, H., Moon, H., Fazzari, MJ., Lim, N., Chen, J. J. and Kodell, R. L. Classification by Ensembles of Random Partitions. Computational Statistics and Data Analysis (2006); 51(12):6166-6179.
7.Strickler HD, Fazzari M, Kovacs A, Isasi C, Napolitano LA, Minkoff H, Gange S, Young M, Sharp GB, Kaplan RC, Cohen M, Gunter MJ, Harris TG, Yu H, Schoenbaum E, Landay AL, Anastos K. Associations of Insulin-Like Growth Factor (IGF)-I and IGF-Binding Protein-3 with HIV Disease Progression in Women. J Infect Dis. (2008); 197(2):319-27 [PMID: 18177247]
8.Thompson RF, Fazzari MJ, Greally JM. Experimental approaches to the study of epigenomic dysregulation in ageing. Exp Gerontol. (2010) Apr;45(4):255-68. [PMID: 20060885]
9.Chow JC, Ciaudo C, Fazzari MJ, Mise N, Servant N, Glass JL, Attreed M, Avner P, Wutz A, Barillot E, Greally JM, Voinnet O, Heard E LINE1 activity in facultative heterochromatin formation during X-chromosome inactivation Cell. 2010 Jun 11;141(6):956-69.[PMID: 20550932]
10.Fazzari, MJ and Greally JM. Introduction to Epigenomics and Epigenome-wide analysis. Methods Mol Biol. (2010);620:243-65 [PMID: 20652507]
11. Kenny P, Fazzari MJ, Sparano, J. Clinical Application of Gene Expression Profiling in Breast Cancer, Surg Oncol Clin N Am (2010)
12. Fazzari, M. Prioritization of candidate loci in epigenome-wide methylation studies. JSM Proceedings (2009), Biometrics section. Alexandria, VA: American Statistical Association.
13. Childs G, Fazzari M, Kung G, Kawachi N, Brandwein-Gensler M, McLemore M, Chen Q, Burk RD, Smith RV, Prystowsky M, Belbin TJ, Schlecht NF. Low level expression of microRNA's let7-d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. AJP (2009); Mar;174(3):736-45
14. McLellan, A.S., Dubin, R.A., Jing, Q., Maqbool, S.B., Olea, R., Westby, G., Ó Broin, P., Fazzari, M.J., Zheng, D., Suzuki, M. and Greally, J.M. The Einstein Center for Epigenomics: studying the role of epigenomic dysregulation in human disease. Epigenomics. 1, 33-38 (2009)
15.Fazzari MJ, Kim MY, and Heo, M. Sample Size Determination for Three-level Randomized Clinical Trials with Randomization at the First or Second level. Journal of Biopharmaceutical Statistics. 2013. [In Press]